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Abstract

Introduction. The latest histological classification of lung adenocarcinoma includes lepidic,
acinar, papillary, micropapillary, and solid as subtypes. Testing these subtypes for their
prognostic and predictive value is an ongoing scientific challenge. The present research article
aims to describe the influence this classification has on patient survival.
Materials and Methods. Thirty-three patients were included in the trial. The most important
enrollment criterion was the clear specification of the adenocarcinoma subtype in the pathology
report. Patients were stratified into three groups which included the adenocarcinoma pathological
subtypes as follows: lepidic (LEP), acinar and papillary (ACN/PAP), and micropapillary/solid
(MIP/SOL). The primary endpoint was progression-free survival. Other endpoints included
overall survival.
Results. The lepidic subtype of ADC had superior PFS and OS, regardless of stage. Papillary
and acinar subtype showed an intermediate prognosis, whereas micropapillary and solid subtypes
were the most aggressive.
Conclusions. The experience of this single center confirmed data in the literature. Further
studies are needed to demonstrate all the possible implications of this pathology classification.
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✓ The standardization of pathological assessment in lung ADC is essential for both early
and advanced stages.
✓ The lepidic subtype of ADC carries the best prognosis for PFS and OS, whereas
micropapillary and solid subtypes are considered the most aggressive.
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Introduction

were made because some of them included too few
patients for clinical significance. All patients were
Lung cancer is currently the most frequent
followed from diagnosis until death for any cause. If
neoplastic disease. Even if measures to reduce smoking
death did not occur by the end of follow-up, the patients
in the population have succeeded in lowering the rate of
were censored.
lung squamous carcinoma, the incidence of lung
The primary endpoint was progression-free
adenocarcinoma (ADC) is rising (1). As opposed to
breast and prostate cancer, where pathological subtypes survival, with a secondary endpoint of overall survival.
and tumour grading influence both prognosis and Follow-up was represented graphically using the Kaplan
treatment decisions, ADC of the lung had no Meier curve. Statistical analysis was processed using
standardized pathological classification until recently, SPSS Statistics version 20.
so cancers were frequently reported as mixed
Results
histologies. For many years, it was considered that lung
ADC was histologically too heterogeneous to permit
Of the total number of patients (n=33), 27,3% (n=9)
classifying. Most of the samples have components of all were stage I, 30,3% (n=10) stage II, and 42,2% (n=14)
types, with one being predominant. Bronchioloalveolar stage III. Nodal involvement was distributed as follows:
carcinoma is the exception to this paradigm, being well N1- 30,3%, N2- 27.3%, and N3- 12.1%. Mean age at
known to be a pure lepidic tumour.
diagnosis was 59.8 years with a maximum of 78 and a
In 2011, as the International Association for the
minimum of 73, standard deviation 9,78.
Study of Lung Cancer (IASLC) and the American
51.5% (n=16) of patients underwent pneumectomy
Thoracic Society (ATS) issued a novel classification of
lung ADC, a search for prognostic significance began. and 48.5% (n=16) less extensive surgery. The frequency
ADC was then classified as lepidic (LEP), acinar of the pathological subtypes were: LEP-12.1% (n=4),
(ACN), papillary (PAP), micropapillary (MIP), and ACN/PAP -63.6% (n=21), MIP/SOL- 24.2% (n=8).
solid (SOL). These subtypes are the foundation of the 84.8% (n=28) were assigned to some type of adjuvant
new WHO classification system of lung ADC based treatment (Table 1).
mainly on tumour architecture (2). Some histological
subtypes of lung ADC (stage I) benefit more from Table 1. Clinical and demographic characteristics
adjuvant treatment, as recent publications have of patients
demonstrated (3). The prognostic implications in more
MicropapiAcinar/
advanced stages have yet to be demonstrated. The Characteristic
Lepidic
Papillary lary/Solid
present trial is meant to illustrate the experience of a
Male
1
11
6
single institution on this matter.
Female
3
10
2
Stage
(TNM)
Materials and Methods
I
2
5
2
Thirty-three patients were enrolled in this
II
1
7
2
prospective, observational trial. The patients were
III
1
9
4
treated in only one center, Elias University Emergency
N stage
Hospital, Clinic of Oncology, Bucharest. Enrollment
0
2
5
3
began in 2015 and inclusion criteria included: diagnosis
1
1
8
1
of lung adenocarcinoma, stages I-III, and treated with
2
1
6
0
surgery/ chemotherapy/ radiochemotherapy in any
3
0
2
2
combination. The most important enrollment criterion
T stage
was the clear specification of the adenocarcinoma
1
2
4
1
subtype in the pathology report. No ’mixed’ histologies
2
1
7
4
were included, even if they specified one predominance.
3
1
10
3
Patients were stratified into three groups which included
Type of
the following pathological subtypes of adenocarcinoma: surgery
Pneumoectomy 2
12
3
lepidic (LEP), acinar and papillary (ACN/PAP), and
Other
2
9
5
micropapillary/solid (MIP/SOL). These associations
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The rate of recurrence for stage I and II was 45%
PFS was then stratified for each stage for the three
during the 41 months of follow-up.
subtypes. The results are represented in Figure 3.
Progression-free survival (PFS) in the three
adenocarcinoma subtype groups is represented in Figure
2. Mean time to progression in the LEP group was 34.3
months, whereas in the ACN/PAP and MIP/SOL
subgroups, the mean time was 17.6 months and 8.3
months respectively. Log Rank (Mantel-Cox) test value
was 11.5, p=.003.

Figure 1. Kaplan Meier curve for
progression-free survival in the three
subgroups (LEP, ACN/PAP, MIP/SOL)
Overall survival for the same three subgroups is
represented in Figure 2. Mean survival time in the LEP
group was 29 months, 29 months in the ACN/PAP
group, and 17.5 months in the MIP/SOL group. Log
Rank (Mantel-Cox) test value was 2.51, p=.285.

Figure 2. Kaplan Meier curve for overall
survival for the LEP, ACN/PAP and
MIP/SOL subtypes

Figure 3. Kaplan Meier curve for PFS for
the LEP, ACN/PAP and MIP/SOL
subtypes stratified by stage.
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Discussions
In the present trial, most patients were stage II, and
the most frequent nodal involvement was N2. The most
frequent pathological subtypes were ACN/PAP, which
is consistent with recent literature data (4). The LEP
subgroup had clear PFS advantage, followed by
ACN/PAP subgroup. The reason this trial was designed
with PFS as the primary endpoint instead of OS is the
relatively short time of follow up (maximum 41
months). Therefore, the present data can be considered
a preliminary analysis, as patients will continue to be
followed. One of the weak points of this analysis is the
small number of enrolled patients and the small
proportion of patients with lepidic ADC (only 4).
Because of these small subgroups, some analyses, for
example, PFS in stage II patients, cannot be considered
reliable.
Another consideration is the lack of standardization
in pathological assessment, done by more than one

provided pathological analyses are high volume ones (8,
9).
The recurrence rate reported for the early stage of
lung ADC is 50%, consistent with the findings of the
present trial. Given this high rate of recurrence, the
necessity for prognostic and predictive biomarkers has
emerged. Several molecular biomarkers (like ERCC1 or
KRAS) have been studied in an attempt to establish
which subtypes benefited most from adjuvant
chemotherapy, but studies have not provided consistent
evidence (10). Therefore, the data presented in the Tsao
trial is important (7).
A question that still needs to be addressed is the
prognostic significance of the papillary subtype. Trials
that have focused on this issue have yielded different
results. In the Australian population, for example, better
survival was reported in the papillary subgroup,
compared to the micropapillary or the solid ones (10,
11). But results were different in the Japanese
population, with a study reporting similar outcomes in

observer in 3 centers of Pathology. WHO recommends
that the entire sample should be fragmented in parts of all three subtypes (12, 13). One exciting hypothesis
5%, so as to establish a predominant pathological implies that early stage papillary ADC has a different
subtype. In our trial, the most suggestive sample of the prognosis in radiochemotherapy-treated patients
resected/ biopsied specimen was selected and analyzed compared with chemotherapy-only patients. Whether
this subtype is more sensitive to combined therapeutical
(2, 5).
The superiority of progression free survival and modalities awaits further study (14).
The prognostic implication of the minority
overall survival in the lepidic subtypes has also been
component of the tumour is still a topic for debate.
confirmed in larger trials (6).
Several attempts related to this minority component
The classification system has proved its utility in
have been made, yet possible correlations regarding
treatment decisions as well, especially for early-stage
survival or other endpoints are still unclear (3).
lung cancer. A clinical trial by Tsao et al. was the first However, some trials suggest that the non-lepidic
to demonstrate that MIP/SOL histology early stage lung component of an early stage tumour is the only one that
ADC benefits most from adjuvant chemotherapy. This carries prognostic significance. A bold proposal was to
trial, which included 575 patients, demonstrated PFS insert this information in the T stage of the TNM system,
and disease-related PFS benefit in the lepidic subgroup, but stronger statistical support is needed (11).
but failed to prove benefit on OS (7).
In our trial, the superiority of survival in the lepidic Conclusions
To summarize, the lepidic subtype of ADC carries
subgroup was also statistically non-significant.
Variation among observers/assessors is an issue that was the best prognosis for PFS and OS, regardless of stage.
addressed in the consensus that issued the novel Papillary and acinar subtypes carry an intermediate
classification, and data in the literature demonstrated prognosis, whereas micropapillary and solid subtypes
that the most concordant results are ones describing the are considered the most aggressive. The standardization
solid subtype. It seems that this subtype is the easiest to of pathological assessment in lung ADC is essential for
recognize. The experience of the observer is also both early and advanced stages. Further studies are
paramount, and pathological assessment should be done needed to demonstrate the many possible implications
in a specialized center. In our trial, all three centers that of this histological classification.
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